U.S. market Closed. Opens in 4 hours 10 minutes

CERE | Cerevel Therapeutics Holdings, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312015-08-312014-08-312013-08-312012-08-31
RevenueN/AN/AN/AN/AN/A2.72M2.40M5.24M5.37M
Cost of Revenue5.63M4.90M2.73M397.00KN/A5.27M3.02M6.25M2.38M
Gross Profit-5.63M-4.90M-2.73M-397.00KN/A-2.55M-617.00K-1.00M2.99M
Operating Expenses441.64M367.85M220.10M149.12M83.46M30.90M31.66M37.83M31.79M
Selling, General & Admin107.00M87.59M58.24M45.81M33.17M15.95M14.48M15.19M12.63M
Research & Development334.64M280.26M161.85M103.30M50.29M9.68M14.16M16.40M19.16M
Other Operating ExpensesN/A6.88M-5.39M-3.27M9.00K5.27M3.02M6.25MN/A
Operating Income-447.26M-367.85M-220.10M-149.12M-83.46M-28.18M-29.26M-32.59M-28.80M
Other Expenses / Income14.93M16.50M-5.24M-3.05M-44.88M22.00K-63.00K80.00K-605.00K
Before Tax Income-432.34M-351.35M-225.33M-152.17M-128.34M-28.16M-29.32M-32.51M-29.41M
Income Tax Expenses503.00K160.00K-2.89M-24.00K45.00K-1.00K-1.00K-1.00K3.00K
Net Income-432.84M-351.51M-222.45M-152.14M-128.39M-28.16M-29.32M-32.51M-29.41M
Interest Expenses10.57M9.62MN/AN/AN/A30.00K68.00KN/A560.00K
Basic Shares Outstanding162.06M151.27M136.58M73.64M127.12M14.24M14.24M14.24M14.24M
Diluted Shares Outstanding162.06M151.27M136.58M73.64M127.12M6.17M36.21M14.24M13.49M
EBITDA-441.64M-367.85M-220.10M-149.12M-36.84M-27.47M-27.74M-30.60M-26.79M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%-1,009.93%-1,153.79%-583.64%-498.75%
EBIT-421.77M-341.73M-225.33M-152.17M-128.34M-28.13M-29.25M-32.51M-28.85M
EBIT Margin0.00%0.00%0.00%0.00%0.00%-1,034.08%-1,216.89%-620.10%-537.09%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312015-08-312014-08-312013-08-312012-08-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙